Michele Hu is a Consultant Neurologist at Oxford University Hospitals, and Senior Clinical Fellow in the Department of Clinical Neurology at the Nuffield Department of Clinical Neurosciences, University of Oxford. After obtaining her medical degree from the University of London in 1993, Michele’s interest in Parkinson’s disease started in 1998 when she was awarded an Action Research Training Fellowship to study brain function in Parkinson’s disease patients using MRI and PET brain imaging techniques. In 2001 she was awarded her PhD based on this work, and went on to train in Parkinson’s disease and movement disorders at the National Hospital for Neurology and Neurosurgery, Royal Free Hospital and King’s College Hospital, London.
Since commencing her consultant appointment in 2005, Michele has set up a clinical Parkinson’s disease, atypical parkinsonism and movement disorders service in the John Radcliffe Hospital, Oxford University Hospitals NHS Trust (website for Oxford Movement Disorders Group: http://www.ndcn.ox.ac.uk/research/oxford-movement-disorders-group;d=RENO). She is an appointed member of the Parkinson’s Disease Clinical Study Group and Parkinson’s Portfolio Management Group of the National Dementias and Neurodegenerative Disorders Network (DeNDRoN) and is NIHR Thames Valley Research Director for Parkinson’s disease. She is a member of the Oxford Parkinson’s Disease Centre (website: opdc.medsci.ox.ac.uk) and leads the Clinical Theme for the recently awarded £5 million Monument Discovery Award funded by Parkinson’s UK to understand the earliest pathological pathways in PD. Her current 50% NHS and 50% research funding facilitates translational research in the field of longitudinal cohort studies and biomarkers of early pre-motor and motor Parkinson’s disease.
Awards, Training and Qualifications
- MBBS University of London 1993
- PhD University of London 2001
- FRCP Royal College of Physicians, London 2009
Sources of Funding
- Parkinson's UK 2010- 2015
MBBS FRCP PhD
Senior Clinical Research Fellow
‘Understanding the early pathological pathways to Parkinson’s disease’, Parkinson’s UK Monument Discovery Award, awarded September 2009. The Oxford Parkinson’s Disease Centre applied for this £5 million Discovery Award among national competition in July 2009. This multi-disciplinary project brings together scientists from Oxford University with international expertise in genomics; the development, analysis and utilisation of animal models using the tools of molecular genetics, neuropathology and neuropharmacology; and the analysis of biomarkers including a proteomics study and novel MRI paradigms in a large clinical cohort of 1500 people with Parkinson’s disease. Dr Michele Hu leads the clinical theme in establishing a cohort of early Parkinson’s disease patients recruited from a population base across the Thames Valley, and followed longitudinally over 5 years to develop and validate early PD biomarkers. So far, 1006 participants in total, who comprise Parkinson's and control subjects, and Parkinson's siblings, have been recruited to this study.
Other Research Activities
Dr Michele Hu is currently working with Dr Chrystalina Antoniades and Professor Chris Kennard at the Nuffield Department of Clinical Neurosciences, Oxford University to pilot and develop eye movement saccadometry and hand tapping measurements in early and premotor Parkinson’s patients. She is research director for Parkinson’s disease in the Thames Valley Dementias and Neurodegenerative Disease Research Network (DeNDRoN) and a member of the national DeNDRoN Parkinson’s Clinical Study Group, which aims to promote high quality research in neurodegenerative disorders.
Quantifying activities of daily living impairment in Parkinson's disease using the Functional Activities Questionnaire.
Becker S. et al, (2021), Neurol Sci
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
Vijiaratnam N. et al, (2021), BMJ Open, 11
Validation of α-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
Jiang C. et al, (2021), Mov Disord
Parkinson's Disease Subtypes: Critical Appraisal and Recommendations.
Mestre TA. et al, (2021), J Parkinsons Dis
Olfactory Testing in Parkinson's Disease & REM Behavior Disorder: A Machine Learning Approach.
Lo C. et al, (2021), Neurology